Does serum carcinoembryonic antigen elevation in patients with postoperative stage II colorectal cancer indicate recurrence? Comparison with stage III

Journal of Surgical Oncology

Volumn 102, Issue 2, 2010, Pages 154-157

  Hara, Masayasu ^a   Sato, Mikinori ^a   Takahashi, Hiroki ^a   Takayama, Satoru ^a   Takeyama, Hiromitsu ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

CEA; Colorectal cancer; Follow up; Recurrence; Stage II

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ACCURACY; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIODIAGNOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77955118021     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21599     Document Type: Article

References (21)

1. Desch CE, Benson AB III, Somerfield MR, et al.: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23:8512-8519.
2. Locker GY, Hamilton S, Harris J, et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327.
3. Tveit KM: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer. Ann Oncol 2003;14:1006-1007.
4. Duffy MJ, van Dalen A, Haglund C, et al.: Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718-727.
5. Duffy MJ: Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? Clin Chem 2001;47:624-630.
6. Duffy MJ, van Dalen A, Haglund C, et al.: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43: 1348-1360.
7. Korner H, Soreide K, Stokkeland PJ, et al.: Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: A receiver operating characteristic curve analysis. Ann Surg Oncol 2007;14:417-423.
8. Bhandari M, Guyatt GH: How to appraise a diagnostic test.World J Surg 2005;29:561-566.
9. Wichmann MW, Lau-Werner U, Muller C, et al.: Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res 2000;20:4953-4955. (Pubitemid 32319057)
10. Fernandes LC, Kim SB, Saad SS, et al.: Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer. World J Gastroenterol 2006;12:3891-3894. (Pubitemid 44028404)
11. De Salvo L, Razzetta F, Arezzo A, et al.: Surveillance after colorectal cancer surgery. Eur J Surg Oncol 1997;23:522-525.
12. Shani A, Ritts RE, Jr., Thynne GS, et al.: A prospective evaluation of the leukocyte adherence inhibition test in colorectal cancer and its correlation with carcinoembryonic antigen levels. Int J Cancer 1978;22:113-119.
13. Clinical practice guidelines for the use of tumor markers in breast, colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996; 14:2843-2877.
14. Levy M, Visokai V, Lipska L, et al.: Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma 2008;55:138-142.
15. Chau I, Allen MJ, Cunningham D, et al.: The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004;22:1420-1429.
16. Hara M, Kanemitsu Y, Hirai T, et al.: Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: Analysis with likelihood ratio and posttest probability in a follow-up study. Dis Colon Rectum 2008;11:1675-1680.
17. Sackett DL, Strauss SE, Richardson WS: Evidence-based medicine: How to practice and teach EBM, 2nd edition. New York: Churchill Livingstone; 2000.
18. Akobeng AK: Understanding diagnostic tests 2: Likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr 2007;96:487-91.
19. Davidson M: The interpretation of diagnostic test: A primer for physiotherapists. Aust J Physiother 2002;48:227-232. (Pubitemid 35021639)
20. Welch JP, Donaldson GA: Detection and treatment of recurrent cancer of the colon and rectum. Am J Surg 1978;135:505-511.
21. Sadahiro S, Suzuki T, Ishikawa K, et al.: Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepatogastroenterology 2003;50:1362-1366.